Phendimetrazine

Phendimetrazine

File:Phendimetrazine.png
Clinical data
Pregnancy category	C (US)
Routes of administration	Oral
Legal status
Legal status	C-III (US)
Pharmacokinetic data
Bioavailability	Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours
Metabolism	hepatic
Elimination half-life	19-24 hours
Excretion	Urinary elimination
Identifiers
IUPAC name 3,4-Dimethyl-2-phenyl-morpholine
CAS Number	634-03-7
PubChem CID	12460
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H17NO
Molar mass	191.27

Indicated for: obesity

Phendimetrazine (Bontril®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

Phendimetrazine is used clinically in the form of phendimetrazine tartrate.

File:Phendimetrazine.jpg

Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.

According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.

External links

• List of psychotropic substances under international control

Template:Pharma-stub Phendimetrazine is listed as a Schedule III substance under the U.S. Controlled Substance Act in the 2007 Drug Identification Bible, pg 615 and under Section 11056(b)(6) California Health & Safety Code.